论文信息 - Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC). - 字舞流文

Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC).

P. Bycott | N. Vogelzang | J. Tarazi | B. Rosbrook | J. Gallardo | V. Stus | A. Bair | S. Al-Shukri | V. Lesovoy | S. Kim